Clinical outcomes associated with anti‐obesity medications in real‐world practice: A systematic literature review. (22nd August 2021)

• Record Type: Journal Article
• Authors: Ahmad, Nadia N.; Robinson, Susan; Kennedy‐Martin, Tessa; Poon, Jiat Ling; Kan, Hong
• Is Part Of: Obesity reviews. Volume 22:Number 11(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-22
• Subjects: anti‐obesity medication -- effectiveness; Obesity -- Periodicals; 616.398005
• DOI: 10.1111/obr.13326
• Languages: English
• ISSNs: 1467-7881

Abstract

Summary: Anti‐obesity medications (AOMs) are efficacious and well tolerated in randomized controlled trials, but findings may not be generalizable to routine clinical practice. This systematic literature review aimed to identify real‐world (RW) evidence for AOMs to treat adults ( ≥ 18 years) with obesity or overweight (BMI ≥ 27 kg/m 2 ). Searches conducted in MEDLINE, Embase, Health Technology Assessment (HTA) Database, National Health Service (NHS) Economic Evaluation Database, and Cochrane Central Register of Controlled Trials for studies of relevant FDA‐approved AOMs yielded 41 publications. Weight loss (WL) was consistently observed, with 14% to 58.6% of patients achieving ≥ 5% WL on orlistat, phentermine/topiramate, naltrexone/bupropion, phentermine, or liraglutide in studies of 3–6 months' duration where this was measured. When cardiometabolic risk factors were assessed, AOMs reduced or had no impact on blood pressure, lipids, or glycemia. RW data on the impact of AOMs on existing obesity‐related comorbidities and mortality were generally lacking. AOMs were associated with various adverse events, but these were of mild to moderate severity and no unexpected safety signals were reported. A pattern of poor adherence and persistence with AOMs was observed across studies. Overall, the review confirmed the effectiveness of AOMs in RW settings but demonstrated large gaps in the evidence base.